Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Difficulty in treating older hepatitis C patients with combination therapy

09.01.2006


A new study in Japan examining the effects of combination therapy on older patients with hepatitis C found more adverse effects necessitating discontinuation of treatment, lowering of dosages, and lower long-term benefits in this age group.



The results of this study appear in the January 2006 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD). Published by John Wiley & Sons, Inc., Hepatology is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/hepatology.

Chronic hepatitis C virus (HCV), the most common cause of liver disease, affects approximately 300 million people worldwide. The virus was seen in the Japanese population decades before the U.S., with the result that HCV patients in Japan are 10 to 15 years older than patients in western countries. The standard treatment is combination therapy with interferon or pegylated interferon (a newer form of the drug that is thought to be more effective) and the antiviral drug ribavirin. However, this treatment tends to be associated with adverse effects that lead to either a dose reduction or discontinuation of therapy in up to 28 percent of patients.


Researchers led by Yoshiaki Iwasaki of the Department of Gastroenterology and Hepatology at Okayama University in Okayama, Japan conducted a study involving 208 HCV patients between December 2001 and July 2003. They classified the patients into three groups: younger than 50 years of age, 50 to 59 years old, and 60 years of age or older and scheduled them for 24 weeks of combination therapy with interferon and ribavirin. Of the 208 patients, 56 percent had to discontinue therapy or reduce their dosage due to adverse effects such as decreased appetite, retinal hemorrhage, and low white blood cell count and the older the patient, the more likely it was that this was the case. In addition, there was a tendency toward a lower sustained virological response (SVR, the absence of HCV for more than 6 months after completing therapy) in the older patient group.

The dose reductions and discontinuation of therapy in this study were much more frequent than in previous studies, which the researchers attribute to the more advanced age of the patients. The fact that older patients had higher rates of impaired kidney function and high blood pressure may have led to more frequent adverse effects. In addition, they note that patients were given high-dose induction therapy of standard interferon, which may render them more susceptible to adverse effects than HCV patients in western countries, where lower doses of interferon or pegylated interferon are the norm.

The results also indicated that for more than 70 percent of the patients, dose reduction and discontinuation of therapy was necessary within the first 12 weeks of therapy, which had a negative impact on SVR, especially in older patients and in cases where the doses of both drugs were reduced. Of the two drugs, reducing ribavirin during the first 12 weeks of therapy seemed to have a greater impact on SVR than reducing interferon.

"The present data demonstrated the importance of considering patient age when treating hepatitis C via combination therapy, especially for patients more than 60 years old," the authors state. "The treatment schedule should be modified, or other therapeutic modalities should be considered for older patients with chronic hepatitis C." They stress the importance of patient education and support to maximize patient compliance in completing the treatment regimen. Although the study involved only Japanese patients, it should be noted that approximately 35,000 new HCV infections occur each year in the U.S.; the proper treatment of older patients with chronic hepatitis C may therefore become an emerging problem in this country.

David Greenberg | EurekAlert!
Further information:
http://www.wiley.com
http://www.interscience.wiley.com/journal/hepatology

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Gold shines through properties of nano biosensors

17.08.2017 | Physics and Astronomy

Greenland ice flow likely to speed up: New data assert glaciers move over sediment, which gets more slippery as it gets wetter

17.08.2017 | Earth Sciences

Mars 2020 mission to use smart methods to seek signs of past life

17.08.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>